BRIEF-Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110
Dec 11 (Reuters) - ARGENX NV:
* TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)